About Eukaryotic translation initiation factor 3 subunit H
Eukaryotic translation initiation factor 3 subunit H (EIF3H) is a protein
from Homo sapiens identified by UniProt accession
O15372, 352 residues long.
MolForge cross-references it against 0 known binders and
71 disease associations.
Target properties
| Protein name | Eukaryotic translation initiation factor 3 subunit H |
| UniProt accession | O15372 |
| Gene | EIF3H |
| Organism | Homo sapiens |
| Length | 352 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (71)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.52
- colorectal cancer · score 0.34
- colorectal adenoma · score 0.29
- heel bone mineral density · score 0.26
- vital capacity · score 0.22
- body height · score 0.21
- self reported educational attainment · score 0.19
- BMI-adjusted waist circumference · score 0.19
- polyp of large intestine · score 0.17
- BMI-adjusted hip circumference · score 0.15
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O15372-F1 | alphafold | PREDICTED | 72.70 | — |
Amino-acid sequence (352 residues)
MASRKEGTGS TATSSSSTAG AAGKGKGKGG SGDSAVKQVQ IDGLVVLKII KHYQEEGQGT EVVQGVLLGL VVEDRLEITN CFPFPQHTED DADFDEVQYQ MEMMRSLRHV NIDHLHVGWY QSTYYGSFVT RALLDSQFSY QHAIEESVVL IYDPIKTAQG SLSLKAYRLT PKLMEVCKEK DFSPEALKKA NITFEYMFEE VPIVIKNSHL INVLMWELEK KSAVADKHEL LSLASSNHLG KNLQLLMDRV DEMSQDIVKY NTYMRNTSKQ QQQKHQYQQR RQQENMQRQS RGEPPLPEED LSKLFKPPQP PARMDSLLIA GQINTYCQNI KEFTAQNLGK LFMAQALQEY NN
Explore Eukaryotic translation initiation factor 3 subunit H with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets